ESC Heart Failure (Aug 2024)

Representativeness of the PIONEER‐HF and PARAGLIDE‐HF in patients hospitalized with acute heart failure

  • Dong‐Yi Chen,
  • Chun‐Chi Chen,
  • Cheng‐Hung Lee,
  • Chi‐Nan Tseng,
  • Shao‐Wei Chen,
  • Shang‐Hung Chang,
  • Tien‐Hsing Chen,
  • Pao‐Hsien Chu,
  • I‐Chang Hsieh,
  • Ming‐Shien Wen,
  • Ming‐Lung Tsai,
  • Ming‐Jer Hsieh

DOI
https://doi.org/10.1002/ehf2.14761
Journal volume & issue
Vol. 11, no. 4
pp. 2259 – 2271

Abstract

Read online

Abstract Aims The PIONEER‐HF and PARAGLIDE‐HF trials aimed to determine the efficacy and safety of the in‐hospital initiation of sacubitril/valsartan in patients hospitalized for AHF. However, whether the inclusion and exclusion criteria of the trials apply to patients encountered in real‐world routine care is unclear. This study aimed to investigate the applicability of the PIONEER‐HF and PARAGLIDE‐HF trials to real‐world AHF patients. Methods and results We identified 28 293 AHF hospitalized patients between August 2008 to August 2017 from the Chang Gung Research Database and classified them into four groups based on left ventricular ejection fraction (LVEF) and trial criteria. Cox proportional hazards models were used to compare the risk of HF hospitalization and cardiovascular (CV) death. We defined PIONEER‐HF eligible (n = 3683) and non‐eligible (n = 3502) patients with an LVEF ≤40%, and PARAGLIDE‐HF eligible (n = 5191) and non‐eligible (n = 5832) patients with an LVEF >40%. Over a mean follow‐up of 3.5 years, the PIONEER‐HF non‐eligible and eligible groups exhibited similar rates of HF hospitalization and CV death (41.1% vs. 41.8%, adjusted hazard ratio [aHR]: 0.95; 95% CI: 0.88–1.04). No significant difference was found in the composite outcome between PARAGLIDE‐HF non‐eligible and eligible groups (36.7% vs. 38.6%; aHR: 0.97; 95% CI: 0.90–1.04). Conclusions Using trial criteria, only 31.3% of AHF patients were eligible for sacubitril–valsartan. Yet, non‐eligible patients demonstrated similar outcomes to eligible patients, indicating a need for further evaluation of sacubitril–valsartan benefits in non‐eligible AHF patients.

Keywords